Time to Buy the Beaten-Down Emerging Market ETFs?
Audentes Therapeutics, Inc. BOLD was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $34.24–$40.05 in the past one-month time frame, witnessed a sharp increase on Friday.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Audentes Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Audentes Therapeutics, Inc. Price
Audentes Therapeutics, Inc. Price | Audentes Therapeutics, Inc. Quote
A better-ranked stock in the Medical – Biomedical and Genetics industry is Athersys, Inc. ATHX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BOLD going up? Or down? Predict to see what others think:Up or Down
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Athersys, Inc. (ATHX) : Free Stock Analysis Report
Audentes Therapeutics, Inc. (BOLD) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research